På denne side bringer DANSK BIOTEK nyheder fra medlemmerne, som på denne måde får mulighed for at blive ekstra eksponeret.

Vi modtager derfor gerne pressemeddelelser og andre nyheder. Send dem til Dorte Dannemann, hjælp af denne formular.

23 Mar 2010

NeuroSearch announces positive Phase III results

The MermaiHD study met the primary endpoint to show an effect on voluntary motor function. In addition, data from the 437 Huntington patients, who participated in the study (= ITT population) show that six months’ (26 weeks) treatment with Huntexil® results in significant improvements in a broader range of voluntary and involuntary motor symptoms associated with the disease. The study was conducted in 32 centres across Europe, and showed a very high compliance with 92% of the patients completing the study and 82% in full compliance with the study.

If you can't find it here or have feedback to our website, please do not hesitate to contact dd@danskbiotek.dk or 28895854

Copyright 2010 Danskbiotek. All rights reserved.